Valuation: Glenmark Pharmaceuticals Limited

Market Cap 640B 6.7B 5.86B 5.41B 5B 9.5B 9.65B 64.76B 25.38B 314B 25.16B 24.62B 1,088B P/E 2026
44.2x
P/E 2027 * 27.2x
Enterprise Value 601B 6.29B 5.5B 5.08B 4.7B 8.91B 9.06B 60.78B 23.83B 295B 23.62B 23.11B 1,021B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.61x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day+1.96%
1 week+4.87%
Current month+2.85%
1 month+4.17%
3 months+4.31%
6 months+9.01%
Current year+11.40%
1 week 2,185.2
Extreme 2185.2
2,293.9
1 month 2,101
Extreme 2101
2,293.9
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 661
Extreme 661
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+4.87%+23.86%+228.94% 6.55B
+2.67%+3.88%+15.92%+87.19% 47.31B
-0.81%+3.80%+67.17%+112.23% 36.04B
+0.66%-1.06%-3.16%+41.21% 12.08B
+0.96%+4.49%+17.88%+99.06% 11.96B
+0.38%+1.95%+34.36%+123.93% 9.05B
-0.08%-0.91%+17.07%+43.71% 6.92B
-1.61%+3.42%+58.05%-3.09% 7.19B
-2.19%+2.95%-21.76%+7.68% 5.9B
+0.88%-1.19%+26.70%+132.72% 4.28B
Average +0.30%+0.22%+23.61%+87.36% 14.73B
Weighted average by Cap. +0.77%+1.55%+29.46%+90.76%

Financials

2026 2027 *
Net sales 153B 1.6B 1.4B 1.29B 1.2B 2.27B 2.31B 15.5B 6.07B 75.19B 6.02B 5.89B 260B 167B 1.75B 1.53B 1.41B 1.3B 2.47B 2.52B 16.87B 6.61B 81.87B 6.56B 6.42B 284B
Net income 20.53B 215M 188M 174M 161M 305M 310M 2.08B 815M 10.08B 808M 790M 34.92B 23.28B 244M 213M 197M 182M 346M 351M 2.36B 924M 11.43B 916M 896M 39.6B
Net Debt -39.29B -412M -360M -332M -307M -583M -593M -3.98B -1.56B -19.3B -1.55B -1.51B -66.84B -37.12B -389M -340M -314M -290M -551M -560M -3.76B -1.47B -18.23B -1.46B -1.43B -63.14B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
09/07/26 2,267.20 +1.96% 427,091
08/07/26 ₹2,223.70 -1.82% 337,287
07/07/26 ₹2,264.90 -0.26% 770,737
06/07/26 ₹2,270.90 +2.71% 600,450
03/07/26 ₹2,211.00 +0.68% 632,010
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,223.70INR
Average target price
2,497.27INR
Spread / Average Target
+12.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock